Backround & Objective: Clostridium difficile associated disease (CDAD) is a matter of grave concern in the hospital environments due to antimicrobial usage.
INTRODUCTION
Clostridium difficile is recognized globally as an important enteric pathogen associated with considerable morbidity and mortality. Widespread outbreaks of CDAD are increasingly being reported worldwide and is believed to be due to the broad-spectrum antimicrobial use 1,2 as well as the use of other drugs such as proton pump inhibitors, 3 immunosuppressives 4 and cancer therapeutics. 5, 6 The elderly and the debilitated patients easily contract the disease predominantly due to the overzealous use of antibiotics. 2, 7 The role of the hospital was not clearly demarcated in earlier epidemiologic studies of C.difficile. 8 As awareness increased; various symptoms present during CDAD were taken into consideration to diagnose the disease clinically. Thus profuse watery, green foul smelling or bloody diarrhoea along with abdominal cramps and fever is regarded as the hallmark of CDAD. Even though diarrhoea is generally a side effect of many commonly used antibiotics, the overgrowth of drug resistant C. difficile -either endogenous in origin or acquired exogenously -can result in nosocomial diarrhoea.
C. difficile produces two highly lethal exotoxinstoxin A and toxin B. Toxin A is primarily an enterotoxin and is associated with extensive damage to the gastrointestinal wall and accumulation of luminal fluid 9 even though it is also a cytotoxin. Toxin B is by and large PDF created with pdfFactory Pro trial version www.pdffactory.com a cytotoxin that appears to come into play after the damage is done by toxin A. 10 Both the toxins open up the tight junctions between the intestinal epithelial cells of the gut and hence aid vascular permeability and also cause haemorrhage.
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Production of toxins A and B by C. difficile is an important factor for CDAD manifestation and the diagnosis of CDAD is based primarily on the detection of these toxins. The combination of the presence of C. difficile in hospitals and the number of people receiving antibiotics and other drugs in these settings can lead to frequent outbreaks of CDAD.
We investigated the clinical and demographic profile of patients whose fecal samples were received in our laboratory and correlated the same with their status. The study was approved by the Ethical Committee of the Institute. (ii) C. difficile toxin assay: C. difficile toxins A and B were detected in the fecal specimens as described earlier 3,12 using purified anti-toxin A and anti-toxin B (kindly provided by Dr. M. Warny, USA). Briefly, 50 µl of 1 in 5 diluted fecal supernatant was taken on a clean glass slide to which ready-to-use C. difficile antitoxin A or B coated latex beads were added. The slide was gently rocked manually and checked for macroscopic agglutination. The fecal supernatant that agglutinated instantly with latex beads coated with anti-toxin A was taken to be positive for toxin A and that which agglutinated with anti-toxin B as positive for toxin B. A known positive fecal sample obtained from a patient with antibiotic associated diarrhea served as the positive control. Two negative controls consisted of (i) an unreactive fecal sample from a healthy subject who had no antibiotic exposure for 6 weeks prior to testing and (ii) uncoated latex beads plus diluted test sample. All positive samples were further subjected to titrations by doubling dilutions of the samples and repeating the procedure. The toxin titer was determined by a positive agglutination reaction with the highest dilution of the fecal supernatant.
MATERIALS AND METHODS (i)
(iii) Demographic analysis: The laboratory records were reviewed for patient demographics, clinical presentation, medical history, therapy etc. Patients of all age groups were included in the study. All prescriptions for antibiotics and other drugs were taken into consideration. During the time of analysis the patients were assigned to two groups (i) Group 1 comprised of those receiving antibiotic and other drugs (RAD) and (ii) Group 2 of those not receiving any antibiotic or drug (NRAD).
(iv) Statistical analysis: The data were expressed by descriptive statistics. The statistical analysis for comparison of RAD and NRAD groups and CDT positive cases in them was carried out by the Chisquare test for qualitative data. p<0.05 was considered statistically significant difference. 
RESULTS (i)

DISCUSSION
The reason why CDAD is the most common in hospital settings is mainly due to clustering of cases in hospitals and even within hospital wards. 13 Diarrhoea leads to dissemination of the pathogen in the hospital environment where they exist for a long time due to spore formation. 14 Elderly patients undergoing antibiotic therapy for surgical procedures are at great risk of acquiring the infection. Even young immunocompromised patients are at constant risk. Acquisition of C. difficile may either result in asymptomatic carriage or end in mortality for patients undergoing antibiotic therapy for unrelated diseases. 15 The identification of patients at risk in a hospital will help the clinicians to promptly diagnose and manage CDAD.
*Some of the patients had two or more co-morbidities. 
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In the present investigation the clinical and demographic profile of 629 patients were reviewed and correlated with their CDT status in order to identify factors most strongly associated with CDAD in our setting. Even though CDT positivity was detected in all age group similar to our earlier report 12 we found that age group below 2 years and between 41-55 years were significantly associated with CDT positivity. The increased rates of CDAD amongst the middle age group in our setting could be due to various reasons inclusive of dissemination of the pathogen by silent reservoirs in the tertiary care hospital and multiple CDAD precipitating factors like underlying diseases and various drugs taken for the treatment. Though CDT positivity was higher in the males, it was not significantly associated with the gender, and might only reflect the increased opportunity for treatment amongst the males.
Antibiotic and other drug receiving group (RAD) was 3.47 times more prone to diarrhoea than the nonreceiving group (NRAD). Similarly the former group was found to be 1.16 times more prone to fever than NRAD. However, interestingly, abdominal pain was not found to be significant in RAD group compared to the NRAD group. Abdominal pain should therefore be regarded as a general clinical symptom of other underlying diseases and may or may not be present in CDAD during the time of testing in high risk patients. A high number (45.8%) of the 629 samples were CDT positive and it was influenced by prior drug usage inclusive of antibiotics and proton pump inhibitors as 81.3% patients in RAD group were CDT positive compared to only 18.7% in the NRAD group (p <0.05), although diarrhea was present in almost all of the CDT positive patients (99.3%).
Amongst the factors that contribute to C. difficile pathogenicity, CDT production is the best characterized and the most important. 16, 17 Colonization of C. difficile may result in a broad spectrum of clinical conditions varying from non-specific diarrhoea to pseudomembranous colitis and CDT may be present in many of them. However the presence of CDT by itself may not necessarily be due to a case of CDAD, but patients having an antibiotic associated diarrhoea and who test positive for CDT are generally regarded to have CDAD. 7, 18 Earlier investigators worked primarily with toxin A whereas others worked mostly with toxin B before the importance of both the toxins in the pathogenicity of CDAD was discovered. These workers may have missed some of the cases where A -B + or A + B -strains of C. difficile were the etiological factors. In the present study both toxins A and B were detected in a large number of patients. Apart from these, toxin A + B -and A -B + cases were also detected in 4-6% of our samples.
Toxigenic isolates of C. difficile differ in amount of toxin production activity depending upon their serogroups. The risk of acquiring diarrhoea depends upon the infecting C. difficile strain. 19 In the present study, data on the strains of C. difficile is not available. Other than this, CDAD rates and severity of the disease are also dependent on the host immune response and the levels of toxin neutralizing antibodies. In the present study, CDT titers ranged from 1 in 5 to 1 in 2560 in the CDT positive patients, with peak titers ranging from 1 in 20 to 1 in 80. Akerlund et al 20 investigated the relationship between fecal CDT levels in a CDAD endemic region and suggested that the broad range of fecal toxin levels observed may be due to coarse measure of diarrhea frequency and to the fact that toxin levels represented only one time point per patient during infection.
In the United States alone, it was estimated that there were about 3 million cases of CDAD every year with approximately 1 billion dollars being spent for healthcare expenses. 2, 21 Due to the prevalence of the global epidemic and hypervirulent strain, efforts should be made to isolate patients with CDAD to minimize the cross contaminations between patients. Identifying patients who are at high risk for severe CDAD early in the course of their infection may have clinicians responsibility and improve outcomes, but predictions are not well known 22 and host factors are also likely to be predictors of illness and death. Das et al 23 reported significantly higher mortality of patients with CDAD on glucocorticoids, compared to those without them, regardless of the severity of CDAD. Bajaj et al 24 also reported that cirrhotics with CDAD have a higher mortality, longer length of hospital stay etc., compared with those without CDAD. Antibiotic and PPI use are risk factors for CDAD development in hospitalized cirrhotics. In our study, among the other drugs taken, PPI use was common and was seen to be associated with CDT positivity. Even among the underlying comorbidities, gastrointestinal diseases were the commonest, followed by malignancy, pulmonary diseases, infectious diseases and hepatic disorders. Halvorson et al 25 reported an unusual case of fatal non-antibiotic associated CDAD following Salmonella serotype Saintpaul gastroenteritis in a previously healthy young person, re-emphasizing the risk of CDAD in the community. Thus studying toxin Clostridium difficile toxin levels in feces influenced by both bacterial and patient factors, contribute to the severity of symptoms in CDAD patients.
Dubberke et al 26 suggest that only diarrhoea stools should be tested for C. difficile or its toxins. In case of non-diarrheal stools, review of patient records is required to ensure that patient has symptoms of C. difficile infection. 27 Repeated stool testing for C. difficile positive cases serves no purpose unless the symptoms resolve with treatment. The degree and extent of C. difficile related paediatric diarrhoea might turn into a lot more worse condition than in adults. 28 Infants are known to have a high number of toxigenic C. difficile and a high amount of toxin A and B in their stools and yet be completely asymptomatic. Such asymptomatic carriers produce a reservoir pool of the pathogen in the hospital environment. In the present study also a significant number of CDT positivity was seen among infants below 2 years.
Genetic subtyping, and binary toxin assays are currently not widely accessible, thereby making patient management difficult. Our results suggest that readily available clinical data such as age and basic laboratory data are correlated with severe CDAD. However, clinical symptoms like diarrhoea, fever and abdominal pain were not found to be significantly associated with toxin positivity, even though both toxin A and B were present in patients presenting with these clinical symptoms. Antibiotics like cephalosporins, penicillins, quinolones etc and drugs like PPI, immunosuppressives and chemotherapeutics were found to be associated with CDT positivity. Therefore hospital should support antibiotic policies that minimize the use of broad spectrum penicillins, cephalosporin and fluoroquinolones, as well as over the counter drugs like proton pump inhibitors.
